From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Russell 1000 Component
Founded2010 in Waltham, Massachusetts
Number of employees
286 (2016)

Tesaro is a public pharmaceutical company based in Waltham, Massachusetts. They focus on drug development for cancer.

In December 2018, GlaxoSmithKline announced it would acquire the company for $5.1 billion.[1]


Tesaro was founded in 2010.[2] The company's first commercial product, Varubi, was approved by the FDA in October 2015.[3] As of 2016, the company had 286 full-time employees, 59 of whom had a PhD or MD.[4] The company's product Niraparib was granted priority review and was given a target action date of June 2017 by the FDA.[5] In March 2017, Tesaro won approval for its drug Zejula to treat ovarian cancer.[6] On May 31, 2017, it was reported that Tesaro Inc. was exploring a sale.[6]

Products under development[edit]

  • Rolapitant – intravenous form in phase III clinical trials for use in chemotherapy-induced nausea and vomiting
  • Niraparib – PARP inhibitor in clinical trials for breast and ovarian cancer.[7]
  • TSR-042
  • TSR-022


  1. ^ https://uk.reuters.com/article/us-tesaro-m-a-gsk/gsk-slides-after-buying-cancer-firm-tesaro-for-hefty-5-1-billion-idUKKBN1O218H
  2. ^ "Tesaro". FierceBiotech. Retrieved 2017-02-25.
  3. ^ "TESARO - Quarterly Report". Ir.tesarobio.com. Retrieved 2017-02-25.
  4. ^ "TESARO - Annual Report". Ir.tesarobio.com. Retrieved 2017-02-25.
  5. ^ ESARO (TSRO) Announces Priority FDA Review for Niraparib NDA, Street Insider, December 20, 2016, Archived from the original on December 21, 2016, retrieved June 8, 2017CS1 maint: BOT: original-url status unknown (link)
  6. ^ a b D. Rockoff, Jonathan; Cimilluca, Dana (May 31, 2017). "Tesaro Explores Sale". Wall Street Journal. New York City, New York. Retrieved June 1, 2017.
  7. ^ "2016 Press Release: Niraparib Significantly Improves Outcome of Ovarian Cancer Patients in Landmark Trial". ESMO. Retrieved 2017-02-25.

External links[edit]